Whereas GLS could be targeted for cancer therapy in patients with breast, esophagus, head-and-neck, and blood cancer, GLS2 could be utilized as a prognostic marker for colon, blood, ovarian, and thymoma cancer. The gene discussed is GLS2; the disease is cancer.